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INTRODUCTION 
 
Lung function is an important predictor of mortality [1] 
even in non-smokers, with low adult lung function  
 
being a consequence of poor growth in utero and/or 
childhood and/or excessive decline in adult life [2]. 
Lung function decline in adulthood occurs because of 
anatomical, physiological and immunological age-
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ABSTRACT 
 
Lung function, strongly associated with morbidity and mortality, decreases with age. This study examines whether 
poor adult lung function is associated with age accelerations (AAs). DNA methylation (DNAm) based AAs, lifespan 
predictors (GrimAge and plasminogen activator inhibitor 1-PAI1) and their related age-adjusted measures were 
estimated from peripheral blood at two time points (8-to-11 years apart) in adults from two cohorts: SAPALDIA 
(n=987) and ECRHS (n=509). Within each cohort and stratified by gender (except for estimators from GrimAge and 
PAI1), AAs were used as predictors in multivariate linear regression with cross-sectional lung function parameters, 
and in covariate-adjusted mixed linear regression with longitudinal change in lung function and meta-analysed.  
AAs were found cross-sectionally associated with lower mean FEV1 (Forced Expiratory Volume in one second) (AA-
residuals:P-value=4x10-4; Intrinsic Epigenetic AA:P-value=2x10-4) in females at the follow-up time point only, and 
the same trend was observed for FVC (Forced Vital Capacity). Both lifespan and plasma level predictors were 
observed strongly associated with lung function decline and the decline was stronger in the follow-up time points 
(strongest association between FEV1 and DNAmAge GrimAge:P-value=1.25x10-17). 
This study suggests that DNAm based lifespan and plasma level predictors can be utilised as important factors to 
assess lung health in adults. 
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related changes in the lung [3]. with the rate of change 
influenced by both genetics [4] and environmental 
exposures including smoking, occupational exposures 
and air pollution [5–7]. However, the exact mechanisms 
contributing to lung function decline are not fully 
understood. 
 
Clinicians and members of the public have long noted 
that some individuals have considerable mismatch 
between their chronological age and their apparent 
biological age. There are now methods to formally 
quantify biological age using biospecimens and one of 
the most widely reported and examined is ‘epigenetic 
aging’ based on peripheral blood DNA methylation 
(DNAm).  
 
There are several methods available to estimate 
epigenetic aging [8–12] and both the Horvath and 
Hannum methods for epigenetic age estimation 
(DNAmAge) have shown high accuracy, with an average 
correlation > 0.90 between chronological and epigenetic 
age [10]. However, these correlations are heterogeneous 
with the Horvath and Hannum methods demonstrating a 
median absolute difference between DNAmAge and 
chronological age of 3.5 [10] and 4.9 years [9], 
respectively. The difference between epigenetic age and 
chronological age is known as age acceleration (AA) and 
both epigenetic age measures and AAs are highly 
correlated with the chronological age. Therefore, 
residuals from regression between epigenetic and 
chronological ages (AAres), using Horvath method, are 
used to determine epigenetic age acceleration. In 
addition, the AA measures are confounded by age-related 
functional decline in blood cell composition. Therefore, 
intrinsic epigenetic age acceleration (IEAA) is used, 
which is independent of age related changes of cellular 
composition of blood, contrasting extrinsic epigenetic 
age acceleration (EEAA), incorporating age-related 
changes in cellular composition in blood and intrinsic 
epigenetic changes [13]. Most recently, DNAm GrimAge 
(DNAmAgegrim), a predictor of lifespan, has been 
developed based on seven DNAm surrogates and a 
DNAm-based estimator of smoking pack-years. The age 
acceleration, known as AgeAccelGrim, can also be 
determined from DNAm GrimAge and henceforth will 
be denoted as AAgrim [14]. In addition, a DNA 
methylation-based surrogate of plasma protein namely 
plasminogen activator inhibitor level (DNAmPAI1) and 
its age adjusted estimator (DNAmPAI1adj), developed in 
the same study, can be good biomarkers of aging.  
Several recent studies, using the Horvath and Hannum 
methods, have found age acceleration is associated with a 
number of diseases and phenotypes, such as obesity [15], 
Alzheimer’s disease [16], Down’s syndrome [17], 
Huntington disease [18], HIV [19], Parkinson’s disease 
[20], and earlier menopause [21]. Horvath’s ‘epigenetic 
clock’ has also been found to be associated with 
mortality. For example in a study of older people (> 68 
years), those with an apparent epigenetic age 5 years 
greater than their chronological age had a 21% increased 
mortality risk over the following 5 years when compared 
to those with no evidence of age acceleration [22]. 
DNAmAgegrim has been found to be a superior predictor 
of time-to-death and DNAmPAI1 has been observed to 
be associated with lifespan, comorbidity count and type 2 
diabetes [14].  
 
To date little is known regarding the association of 
epigenetic aging, as measured from peripheral blood, 
and lung function. The 1936 Mid-Lothian Birth Cohort 
examined the association of various physical measures 
with epigenetic aging in over 1000 elderly adults (mean 
age of 69 ± 0.83 years) followed for between 3 and 6 
years. Lung function, considered as FEV1 (forced 
expiratory volume in one second), was the only one of 
four physiological measures of aging (others being 
cognition, grip strength and walking speed) to show an 
association with DNAmAge, albeit statistically weak 
(P-value = 0.05), and small in effect size (<1 mL change 
in FEV1 per additional year of epigenetic aging). 
Epigenetic aging explained only 0.33% of the variance 
in FEV1 decline [23]. 
 
As part of the Aging Lungs in European Cohorts 
(ALEC) study (www.alecstudy.org) we obtained DNA 
methylation information from 1,496 adults (age range at 
baseline: 37 to 61 years), followed for 8 to 11 years, 
derived from two population-based cohorts specifically 
designed to investigate lung function. The aim of our 
study was to examine the cross-sectional and 
longitudinal association of peripheral blood epigenetic 
signature of aging with lung function in these general 
population-based samples of adults using data on both 
lung function and epigenetic age at two time points 
multiple years apart. 
 
RESULTS 
 
Descriptive statistics of the cohorts at baseline and 
follow-up time points are presented in Table 1. The time 
intervals between the two lung function assessments in 
Swiss study of Air Pollution and Lung and heart 
Disease in Adults (SAPALDIA) and the European 
Community Respiratory Health Survey (ECRHS) were 
8.3 and 10.9 years respectively. The SAPALDIA cohort 
were older with a wider range of ages than the ECRHS 
(baseline: 50.55 ± 11.3 vs. 43.64 ± 6.76 and follow-up: 
58.85 ± 11.26 vs. 54.54 ± 6.78 years). Each cohort had 
similar proportions of men and women.  
 
Within SAPALDIA, chronological age was more highly 
correlated with DNAm Age (baseline = 0.91; follow-up 
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Table 1. Summary of the variables for cohort-specific study populations. 
    Baseline  Follow-up 
  SAPALDIA  ECRHS   SAPALDIA  ECRHS  
N   987 509  987 509 
Age (years)   50.55 ± 11.3 43.64 ± 6.76  58.85 ± 11.26 54.54 ± 6.78 
Female (%)   528 (53.50) 290 (56.98)  Same as baseline Same as baseline 
BMI (kg/m2)   25.8 ± 4.38 25.23 ± 4.25  26.47 ± 4.61 26.73 ± 4.56 
Height (cm)   169.49 ± 9.27 169.59 ± 9.35  168.77 ± 9.4 168.89 ± 9.35 
Smoking Never 407 (41.24) 216(42.44)  401 (40.63) 208(40.87) 
  Ex 297 (30.09) 165(32.41)  366 (37.08) 209(41.06) 
  Current 282 (28.57) 128(25.15)  220 (22.29) 92(18.07) 
Pack years   11.95 ± 18.36 9.28 ± 14.89  13.36 ± 20.19 14.02 ± 32.08 
Education
†
 
1 54 (5.48) 66 (12.97)  Same as baseline Same as baseline 
2 644 (65.25) 148 (29.08)  Same as baseline Same as baseline 
  3 288 (29.18) 295 (57.96)  Same as baseline Same as baseline 
Ever asthma   124 (12.56) 79 (15.52)  111 (11.25) 95 (18.66) 
FEV1 (L)   3.25 ± 0.83 3.41 ± 0.78  2.96 ± 0.84 2.95 ± 0.75 
FVC (L)   4.35 ± 1.05 4.25 ± 0.97  4.05 ± 1.06 3.92 ± 0.97 
FEV1/FVC   0.75 ± 0.07 0.8 ± 0.06  0.73 ± 0.08 0.75 ± 0.06 
Data are presented as n (%) for categorical and mean ± SD for continuous variables. 
† For SAPALDIA: 1: Low (primary school); 2: Middle (secondary school, middle school or apprenticeship); 3: High (Technical 
College or University). For ECRHS: education finishes at 1: ≤16 year; 2: 17-19 year; 3: 20+ years. 
 
Table 2. Summary of chronological and DNAmAge derived from methylation values presented as mean ± SD.  
 N Age (years) DNAmAge R MAD 
SAPALDIA (baseline) 987 50.55 ± 11.3 52.07± 10 0.91 3.4 
SAPALDIA (follow-up) 987 58.85± 11.26 58.5 ± 9.78 0.89 3.3 
ECRHS (baseline) 509 43.64 ± 6.76 47.04 ± 8.32 0.64 3.8 
ECRHS (follow-up) 509 54.54 ± 6.78 55.75 ± 7.43 0.71 2.9 
R = correlation between chronological and DNAmAge. Here DNAmAge has been calculated using Horvath method. MAD = 
Median Absolute Deviation. 
 
= 0.89) than in the ECRHS (baseline = 0.64; follow-up 
= 0.71). However, the median absolute deviation 
suggested little variability and the probability of outliers 
in estimated DNAmAge was low (Table 2).  
 
Cross-sectional association between lung function 
and age acceleration at baseline and follow-up time 
point separately 
 
Results from linear models examining associations of 
forced expiratory volume in one second (FEV1) with age 
acceleration at each time point cross-sectionally within 
SAPALDIA and ECRHS are presented in Table 3. Effect 
estimates were larger in women than men and reached 
statistical significance (P-value < 0.05) at follow-up time 
point in women only. In women, at the follow-up  
time point, FEV1 was associated with AAres (P-value = 4 
x 10-4), where with one year increase of AAres, there was 
a decrement of 9.52 mL in FEV1 (CI: -14.77 mL/yearAA 
to −4.28 mL/yearAA,). The same was been observed for 
IEAA, where FEV1 was 11.30 mL lower per  
year increase of IEAA (95% CI: -17.21 mL/yearIEAA to 
−4.20 mL/yearIEAA and P-value = 2 x 10-4). A  
marginal association between EEAA and FEV1 was 
observed in the same time point for female subjects 
(estimate = -5.11 mL/yearEEAA; 95% CI: -10.16 
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Table 3. Cross-sectional meta-analysis results of association between age acceleration and FEV1 and FVC in SAPALDIA 
and ECRHS cohorts. 
  Baseline  Follow-up 
Lung 
functions 
Sex Age acceleration Estimate 
Lower 
bound 
Upper 
bound 
P-value  Estimate 
Lower 
bound 
Upper 
bound 
P-value 
FEV1 Male AAres -1.27 −9.16 6.62 0.75  -5.39 −14.48 3.69 0.25 
  IEAA -2.47 -10.52 5.58 0.55  -5.16 -14.35 4.04 0.44 
  EEAA -0.94 -8.44 6.55 0.81  -6.32 -15.24 2.59 0.17 
 Female AAres -3.02 -9.17 1.34 0.14  -9.52 −14.77 −4.28 4 x 10-04* 
  IEAA -5.00 -10.60 0.60 0.08  -11.30 -17.21 -4.20 2 x 10-04* 
  EEAA -4.35 -9.39 0.69 0.09  -5.107 -10.16 0.01 0.05* 
FVC Male AAres -4.25 -13.31 4.82 0.36  -10.83 -20.95 -0.71 0.04* 
  IEAA -5.04 -14.30 4.22 0.30  -9.29 -19.57 0.99 0.08 
  EEAA 0.69 -7.85 9.23 0.87  -4.69 -10.46 1.26 0.12 
 Female AAres -4.61 -10.64 1.42 0.13  -9.31 -15.42 -3.20 0.003* 
  IEAA -5.21 -11.65 1.23 0.11  -10.49 -17.37 -3.60 0.003* 
  EEAA -8.06 -17.90 1.78 0.11  -4.86 -10.76 1.03 0.11 
Here, Estimate = difference in lung function per year of epigenetic age acceleration (mL/year). Negative values denote that 
with every year of increase in epigenetic age acceleration, FEV1 decreases and vice-versa; Lower and upper = lower and upper 
ranges of 95% confidence interval of estimates; P-value = p-values from meta-analyses. 
 
mL/yearEEAA to 0.01 mL/yearEEAA, P-value = 0.05). 
(Table 3, Figure 1). EEAA was found marginally 
significantly associated (P-value = 0.05) with only 
FEV1, in women at the later time point. 
 
A similar association for women at the later time point 
was found for forced vital capacity (FVC) (AAres: -9.31 
mL/year; 95% CI: -15.42 mL/year to −3.20 mL/year, P-
value = 0.003 and IEAA: -10.49 mL/year; 95% CI: -
17.37 mL/year to −3.60 mL/year, P-value = 0.003) 
(Table 3) and for FEV1/FVC, IEAA was found 
associated (Supplementary Table 1C).  
 
In men, only AAres was found to be significantly 
associated with FVC (-10.83 mL/year; 95% CI: -20.95 
mL/year to −0.71 mL/year, P-value = 0.04) from the 
follow-up. 
 
Association between lung function and age 
acceleration from repeated measures at baseline and 
follow-up time points combined 
 
In women, there was evidence for a weak association 
of lower FEV1 with EEAA (estimate = -3.58 mL/year; 
95% CI: -7.21 mL/year to 0.04 mL/year and P-value = 
0.05) (Table 4; Figure 2). There was no evidence that 
age acceleration is associated with lung function in 
men (Supplementary Table 2A). 
Association between longitudinal change in 
epigenetic age acceleration and change in lung 
function changes over follow-up 
 
A linear model was used to investigate whether the 
change in biological aging between baseline and follow-
up was associated with rate of change in lung function 
between the two time points. Both cohorts showed no 
association of lung function decline with change in 
biological age acceleration. 
 
A weak association of rate of FEV1 change with 
biological age acceleration derived from IEAA (0.52 
mL/year of epigenetic age acceleration; 95% CI: -0.02 
mL/epigenetic year to 1.05 mL/ epigenetic year and P-
value = 0.06) was observed in men (Supplementary 
Table 3). This same trend was not seen in women (0.18 
mL/year of epigenetic age; 95% CI: -0.15 
mL/epigenetic year to 0.05 mL/ epigenetic year and P-
value = 0.2). 
 
Effect of menopause on lung function and epigenetic 
age acceleration 
 
We incorporated a variable indicating menopausal 
status (pre-, peri-, and post-menopausal) at follow-up 
for the 528 SAPALDIA and 223 ECRHS women. AAres 
and IEAA at follow-up remained associated with FEV1 
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at follow-up in women (AAres: -9.99 mL/year; 95% CI: 
-16.03 mL/year to −3.96 mL/year and P-value = 0.001 
and IEAA: -10.81 mL/year; 95% CI: -17.12 mL/year to 
−4.49 mL/year and P-value = 0.001). However, the 
effect size of FEV1 for female samples for the follow-up 
time point was marginally reduced. The association 
between FVC, and AAres and IEAA also remained 
significant following adjustment for menopausal status 
(Table 5). Comparison of the meta-analyses with and 
without menopausal status using ANOVA showed no 
significant differences (Supplementary Table 4).  
 
The stratified cross-sectional analysis of female samples 
showed association of marginal significance (P-value = 
0.057) in lung function (FEV1) decline (-119 mL; 95% 
CI: 222 mL to 3mL) in post-menopausal women 
compared to with pre-menopausal women 
(Supplementary Table 5). No association was observed 
between menopausal status and age acceleration 
measures (Supplementary Table 6). 
 
Age stratified analysis in females 
 
Significant associations between lung function (FEV1 
and FVC) and age acceleration (AAres and IEAA) were 
observed both in male and female samples in the cross- 
sectional age stratified analysis. AAres and IEAA were 
found to be significantly associated with FEV1 in age
 
 
 
Figure 1. Cross-sectional meta-analysis results for FEV1  of males and females in SAPALDIA and ECRHS. (A) Mean change in FEV1 
(mL) per year of intrinsic epigenetic age acceleration at baseline; (B) Mean change in FEV1 (mL) per year of intrinsic epigenetic age 
acceleration at follow-up. The estimates have been measured with 95% confidence interval in mL/year. 
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Table 4. Meta-analysis results of repeat cross-sectional association between age acceleration and FEV1 in SAPALDIA 
and ECRHS cohorts from two time points (baseline and follow-up). 
 Age acceleration Estimate Lower bound Upper bound P-value 
Male AAres 1.20 -3.41 5.81 0.87 
 IEAA 3.23 -1.21 7.68 0.9 
 EEAA -5.03 -11.56 1.51 0.13 
Female AAres -1.56 -4.10 0.99 0.13 
 IEAA -1.38 -4.23 1.47 0.19 
 EEAA -3.58 -7.21 0.04 0.05 
Here, Estimate = changes in lung function per year of epigenetic age acceleration (mL/year). Negative values denote that with 
every unit of increase in epigenetic age acceleration, FEV1 decreases and vice-versa; Lower and upper = lower and upper 
ranges of 95% confidence interval of estimates; P-value = p-values from meta-analyses. 
 
groups 50 – 60 and 60 – 70 in female samples 
(Supplementary Table 7A). The same trend was 
observed for FVC (Supplementary Table 7B). No 
significant association was observed for FEV1/FVC 
(Supplementary Table 7C). IEAA were found to be 
significantly associated with both FEV1 and FVC in age 
groups 50 – 60 in males. However, while consistent 
lung function decline (for FEV1 and FVC) per 
epigenetic year (for AAres and IEAA) is found up to 70 
years in females, the same trend is not observed in 
males (Figure 3, Supplementary Figure 2).  
Cross-sectional association between lung function 
and DNAmAgegrim, AAgrim, DNAmPAI1 and 
DNAmPAI1adj at baseline and follow-up time point 
separately 
 
Strong associations between lung function and 
DNAmAgegrim and AAgrim were observed respectively in 
the cross-sectional analyses for both baseline and 
follow-up time points (Table 6). The rate of changes in 
lung function declines are found stronger in follow-up 
years than that of the baseline for both DNAmAgegrim 
 
 
 
Figure 2. Linear mixed model meta-analysis results for FEV1  of males and females in SAPALDIA and ECRHS for two time 
points (baseline and follow-up). The estimates have been measured with 95% confidence interval in mL/year. 
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Table 5. Meta-analysis results of repeat cross-sectional association between age acceleration and FEV1 in SAPALDIA 
and ECRHS cohorts from two time points (baseline and follow-up) in women (SAPALDIA: n=528; ECRHS: n=290), 
adjusted for menopausal status. 
Lung functions Age acceleration Estimate Lower estimate Upper estimate P-value 
FEV1 AAres -9.99 -16.03 -3.96 0.001* 
 IEAA -10.81 -17.12 -4.49 0.001* 
 EEAA -5.21 -10.51 0.1 0.06 
FVC AAres -10.23 -17.25 -3.22 0.004* 
 IEAA -10.97 -18.32 -3.63 0.003* 
 EEAA -5.86 -12.00 0.28 0.06 
FEV1/FVC AAres -0.0008 -0.002 0.0002 0.108 
 IEAA -0.0008 -0.001 0.0003 0.138 
 EEAA -0.0007 -0.002 0.0005 0.255 
Estimate = difference in lung function per year of epigenetic age acceleration (mL/year for FEV1 and FVC). Negative values 
denote that with every unit of increase in epigenetic age acceleration lung function decreases and vice-versa; Lower and 
upper = lower and upper ranges of 95% confidence interval of estimates; P-value = p-values from meta-analysis. 
 
 
 
Figure 3. Age stratified analyses comparing association between lung and age accelerations. (A) Comparison between association 
between FEV1 and age accelerations (AAres and IEAA); (B) Comparison between association between FVC and age accelerations (AAres and 
IEAA). X-axis represents stratifications by 10 years intervals. Y-axis represents the estimates (changed in lung function per year of epigenetic 
age acceleration in mL/year) from the linear models with 95% confidence intervals. 
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Table 6. Cross-sectional meta-analysis results of association between DNAm GrimAge (DNAmAgegrim) and its age-
adjusted measure (AAgrim) with lung function in SAPALDIA and ECRHS cohorts. 
Lung 
functions 
 Baseline  Follow-up 
 Estimate 
Lower 
bound 
Upper  
bound 
P-value  Estimate 
Lower 
bound 
Upper 
bound 
P-value 
FEV1 DNAmAgegrim -12.72 -17.91 -7.52 1.62 x 10-06*  -30.14 -37.05 -23.23 1.25 x 10-17* 
 AAgrim -11.96 -17.17 -6.76 6.67 x 10-06*  -29.35 -36.32 -22.39 1.42 x 10-16* 
           
FVC DNAmAgegrim -7.56 -13.59 -1.53 0.01*  -29.42 -37.46 -21.39 7 x 10-13* 
 AAgrim -6.64 -12.69 -0.59 0.03*  -28.48 -36.57 -20.39 5.25 x 10-12* 
           
FEV1/FVC DNAmAgegrim -0.001 -0.002 -0.0005 6.68 x 10-04*  -0.002 -0.003 -0.001 4.85 x 10-06* 
 AAgrim -0.001 -0.002 -0.0005 7.25 x 10-04*  -0.002 -0.003 -0.001 7.06 x 10-06* 
Here Estimate = changes in lung function per year of epigenetic age and age acceleration (mL/year for DNAmAgegrim; 
mL/yearAA for AAgrim). Negative values denote that with every year of increase in epigenetic age acceleration, lung function 
decreases and vice-versa; Lower and upper = lower and upper ranges of 95% confidence interval of estimates; P-value = p-
values from meta-analyses. 
 
(FEV1: -12.72 mL/year to -30.14 mL/year; FVC: -7.56 
mL/year to -29.42 mL/year; FEV1/FVC: -0.001 to -
0.002) and AAgrim (FEV1: -11.96 mL/year to -29.35 
mL/year; FVC: -6.64 mL/year to -28.48 mL/year; 
FEV1/FVC: -0.001 to -0.002), and the same trend is 
observed for AAgrim. Similar strong associations 
between lung functions (FEV1 and FVC) and 
DNAmPAI1 and DNAmPAI1adj were observed 
respectively in the cross-sectional analyses for both 
baseline and follow-up time points (Table 7). Though 
no association was found between FEV1/FVC, and 
DNAmPAI1 and DNAmPAI1adj at baseline time point, 
a significant association was still observed at the 
follow-up time point. However, association between 
FEV1/FVC with DNAmAgegrim, DNAmPAI1 and their 
associated age adjusted measures showed high level 
of heterogeneity at baseline time point (shown  
in heterogeneity p-values in Supplementary Figure 3). 
 
Association between lung function and 
DNAmAgegrim, AAgrim, DNAmPAI1 and 
DNAmPAI1adj from repeated measures at baseline 
and follow-up time points combined 
 
There was evidence for significant associations of 
lower FEV1 and FVC with DNAmAgegrim, AAgrim,, 
DNAmPAI1, and DNAmPAI1adj (Table 8). 
FEV1/FVC is only found significantly associated with 
DNAmAgegrim and AAgrim. However, the associations 
between lung function and DNAmAgegrim and AAgrim 
exhibited high level of heterogeneity (shown in 
heterogeneity p-values in Supplementary  
Figure 4).  
DISCUSSION 
 
Using longitudinal data from two population-based 
cohorts we have examined the association of lung 
function with epigenetic aging and shown that lung 
function is associated with measures of epigenetic age 
acceleration, particularly in women and with increasing 
age. Lung function decline is found to be strongly 
associated with increase in DNA methylation-based 
lifespan predictors, plasma protein levels, and their 
related age adjusted measures. 
 
This is one of the first studies to examine the 
association of age acceleration on lung function over 
more than one time point, and similar to the Mid-
Lothian cohort showing marginal association of FEV1 
with epigenetic age acceleration [30]. In the Mid-
Lothian birth cohort study, participants were of older 
age (70 years at baseline, 76 years at follow-up) than 
the studies used here, whereas the present study 
investigates a wider and younger age range (37 to 61 
years at baseline, 48 to 70 years at follow-up) and a 
follow-up time window of 8 to 11 years for SAPALDIA 
and ECRHS. 
 
Our findings suggest that lung function is associated 
with age acceleration in women and particularly in 
women above age of 50 years. FEV1 was found to be 
declining at a rate of 9.5 mL per year of age 
acceleration using AAres and 11.3 mL per year of age 
acceleration using IEAA. This same trend was observed 
for FVC. This observation was further supported by 
SAPALDIA baseline measures (which were in an older 
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Table 7. Cross-sectional meta-analysis results of association between DNAm based plasminogen activation inhibitor 
1 (DNAmPAI1) and its age adjusted (DNAmPAI1adj) levels with lung function in SAPALDIA and ECRHS cohorts. 
Lung 
functions 
 Baseline  Follow-up 
 Estimate 
Lower 
bound 
Upper 
bound 
P-value  Estimate 
Lower 
bound 
Upper 
bound 
P-value 
FEV1 DNAmPAI1 -0.020 -0.029 -0.011 8.85 x 10-06*  -0.032 -0.041 -0.022 3.63 x 10-11* 
 DNAmPAI1adj -0.019 -0.028 -0.010 2.57 x 10-05*  -0.031 -0.041 -0.022 9.67 x 10-11* 
           
FVC DNAmPAI1 -0.018 -0.028 -0.008 4.84 x 10-04*  -0.029 -0.039 -0.018 2.14 x 10-07* 
 DNAmPAI1adj -0.018 -0.029 -0.008 4.34 x 10-04*  -0.029 -0.040 -0.018 1.53 x 10-07* 
           
FEV1/FV
C 
DNAmPAI1 -1 x 10-6 -2 x 10-6 0.00 0.14  -2x 10-6 
-4 x 10-
6 
-1 x 10-6 0.002* 
 DNAmPAI1adj -1 x 10-6 -2 x 10-6 1 x 10-6 0.29  -2x 10-6 
-3 x 10-
6 
-1 x 10-6 0.003* 
Here, Estimate = difference in lung function (mL) per unit of DNAmPAI1 and DNAmPAI1adj. Negative values denote that with 
every year of increase in epigenetic age acceleration, lung function decreases and vice-versa; Lower and upper = lower and 
upper ranges of 95% confidence interval of estimates; P-value = p-values from meta-analyses. 
 
Table 8. Meta-analysis results of repeat cross-sectional association between DNAmAgegrim, AAgrim, DNAmPAI1, and 
DNAmPAI1adj with lung function in SAPALDIA and ECRHS cohorts from two time points (baseline and follow-up). 
Lung functions  Estimate Lower bound Upper bound P-value 
FEV1 DNAmAgegrim -12.91 -16.63 -9.19 1.03 x 10-11* 
 AAgrim -12.28 -16.03 -8.53 1.37 x 10-10* 
 DNAmPAI1 -0.013 -0.018 -0.008 1.71 x 10-06* 
 DNAmPAI1adj -0.0119 -0.0171 -0.0067 7.81 x 10-06* 
FVC DNAmAgegrim -12.29 -16.92 -7.66 2 x 10-07* 
 AAgrim -11.12 -15.78 -6.45 2.98 x 10-06* 
 DNAmPAI1 -0.020 -0.027 -0.013 1.14 x 10-08* 
 DNAmPAI1adj -0.019 -0.026 -0.012 3.47 x 10-08* 
FEV1/FVC DNAmAgegrim -0.0009 -0.002 -0.0003 0.002* 
 AAgrim -0.0009 -0.002 -0.0003 0.002* 
 DNAmPAI1 1 x 10-7 -8 x 10-6 9 x 10-6 0.99 
 DNAmPAI1adj 9 x 10-7 -8 x 10-6 1 x 10-5 0.83 
Here, Estimate = changes in lung function per year of epigenetic age and age acceleration (mL/year for DNAmAgegrim; 
mL/yearAA for AAgrim) and per unit of PAI-1 for DNAmPAI1 and DNAmPAI1adj. Negative values denote that with every unit of 
increase in DNAmAgegrim. AAgrim, DNAmPAI1, and DNAmPAI1adj lung function decreases and vice-versa; Lower and upper = 
lower and upper ranges of 95% confidence interval of estimates; P-value = p-values from meta-analyses. 
 
group of women) showing a greater effect of age 
acceleration on lung function decline than the ECRHS 
baseline.  
 
Early menopause and post-menopausal status have 
previously been linked with lower lung function [24] 
and menopause has been shown to accelerate epigenetic 
aging of blood [21]. Mendelian randomization studies 
have supported a casual effect of menopause on IEAA 
[25]. Therefore, we postulated that one explanation for 
the stronger association of lung function with age 
acceleration in the older women could be hormonal 
changes. There was a marginally significant association 
(P-value < 0.1) in lung function decline in post-
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menopausal females, compared with pre-menopausal 
females and adjusting for menopausal status resulted 
associations between lung function and age acceleration 
became less strong. However, there were no significant 
differences between the two models. This suggests that 
the onset of menopause may only partially explain the 
stronger associations observed between age acceleration 
and lung function in older female subjects. We also 
observed no significant association between measures 
of epigenetic age acceleration and menopause in our 
study sample. 
 
When the association from the repeated measures from 
two time points was assessed, a marginal association 
was found in female subjects, showing a 3.94 ml 
decline in FVC per year of epigenetic age acceleration 
(AAres). In contrast, while measuring the effect of age 
acceleration on lung function decline between baseline 
and follow-up, there were no significant associations, 
suggesting that decline in lung function is proportional 
to the overall degree of biological aging.  
 
The most interesting results were achieved for DNAm 
based lifespan predictors, DNAmAgegrim and AAgrim, 
which have been found strongly associated with lung 
function for both baseline and follow-up time points and 
combined. However, results for the combined repeated 
time points should be interpreted with caution due to the 
presence of indication of heterogeneity between two 
cohorts. DNAm based plasma protein levels, PAI-1 and 
age adjusted PAI-1, were also observed to be associated 
with lung function both cross-sectionally and in 
combined repeated measures. This association result is 
of particular interest as studies have shown elevated 
PAI-1 level to be associated with lung function decline 
[26, 27], which corroborates with our findings. 
 
One limitation of this study is that we have used 
epigenetic age derived from blood rather than lung 
tissue to assess associations. However, epigenetic aging 
measured from blood has been found to be associated 
with a number of other non-blood related diseases and 
phenotypes such as lung cancer [28], metabolic 
syndrome [15], and developmental disorders [29]. 
Additionally, other physiological changes (such as 
hormonal changes) were not considered. Though we 
have used menopausal status in sensitivity analyses as a 
categorical variable, adding direct measures of sex 
hormone concentrations may provide more insight. 
 
In conclusion, this study suggests that epigenetic age 
acceleration is significantly associated with lung 
function in women older than 50 years. We 
hypothesised that this could be due to menopause. 
However, we have observed that menopause has 
minimal effect and therefore there is possibility of other 
unknown physiological factors at older age in females 
mediating the epigenetic age acceleration effect on lung 
function. While, it is still unknown what exactly 
epigenetic aging from DNA methylation measures, this 
study suggests it can be utilised as one of the important 
factors to assess women’s lung health in old age. DNA 
methylation-based lifespan predictors, such as: DNAm 
GrimAge and plasma protein levels, are strongly 
associated with lung function and therefore this study 
suggests that these can be utilised as important factors 
to assess lung health in adults. 
 
MATERIALS AND METHODS 
 
Study population 
 
Information from 1,496 participants taking part in either 
the Swiss study of Air Pollution and Lung and heart 
Disease in Adults (SAPALDIA) [30, 31] (N=987), or 
the European Community Respiratory Health Survey 
(ECRHS) [32] (N=509) were used in this investigation. 
Measures of lung function, relevant confounders and 
DNAm of the samples were taken at two time points 
(baseline and follow-up).  
 
DNA methylation 
 
DNA for all cohorts was extracted from peripheral 
blood samples taken at two consecutive surveys 8 years 
apart in SAPALDIA and 11 years apart in ECRHS. 
Samples for testing were selected on the basis of having 
lung function complete and high quality of information 
on lung function and relevant confounders. Genome-
wide DNA methylation was quantified using the 
Illumina Infinium HumanMethylation450 Beadchip for 
SAPALDIA samples and using the Illumina Infinium 
HumanEPIC Beadchip for ECRHS samples. Samples 
from two time points derived from the same subject 
were placed next to each other on the array to minimise 
batch effect. Sample and CpG marker quality control 
procedures for epigenetic data of both cohorts are 
described elsewhere [33]. 
 
Measures of epigenetic aging 
 
DNA methylation age (DNAmAge) was calculated 
using (a) the Horvath method [10] using 353 cytosine-
phosphate-guanine sites (CpGs) common to the 
Illumina 450K and EPIC Methylation arrays, and (b) 
Hannum’s method using 71 CpGs [9]. Age acceleration 
residuals (AAres) were calculated from a linear 
regression model by regression of DNAmAge on 
chronological age. Further, AAres measures were 
adjusted for blood cell counts to calculate Intrinsic 
Epigenetic Age Acceleration (IEAA) using the Horvath 
method and Extrinsic Epigenetic Age Acceleration 
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(EEAA) using Hannum method, described in [13]. Age 
acceleration measures (IEAA and EEAA) were 
estimated using an online calculator (available from: 
https://dnamage.genetics.ucla. 
edu/submit). DNAm based GrimAge and its associated 
age acceleration measures (DNAmAgegrim and AAgrim) 
and DNAm-based estimators of plasma proteins and its 
age adjusted level (DNAmPAI1 and DNAmPAI1adj) 
were calculated using the new online calculator 
(available from: https://dnamage.genetics.ucla.edu/new) 
 
Lung function measures 
 
Two objective measures of lung function, forced 
expiratory volume in one second (FEV1) and forced vital 
capacity (FVC), and their ratio (FEV1/FVC) were 
examined. They were measured by trained personnel 
according to the ATS/ERS recommendations [34]. Lung 
function measures for SAPALDIA was obtained from 
2001 and 2010 measurements with correction for change 
in spirometers (SensorMedics to Easy One : ndd Medical 
Technologies, Zurich, Switzerland) [35]. For ECRHS, 
different spirometers were used in each centre (Biomedin 
in the UK, Sensor Medics in Norway and Jaeger 
Pneumolab in Germany) at baseline and the same 
spirometer (Easy One: ndd Medical Technologies, 
Zurich, Switzerland) was used in all centres at follow-up.  
 
Covariates 
 
Analyses were adjusted for age, sex, height (cm), body 
mass index (kg/m2), self-reported history of lifetime 
asthma, level of completed education as a proxy for 
socio-economic status, and smoking status (never, 
former, current) for both time points. The study centres 
were also considered as covariates as the samples were 
distributed over multiple geographical areas.  
 
Statistical analysis 
 
To assess the variability between chronological age and 
DNAmAge, correlation and Median Absolute Deviation 
(MAD) were determined. To assess the association of 
lung function with age acceleration (AA) cross-
sectionally, linear regression was used for each of the 
two time points (approximately 10 years apart) with 
lung function as the outcome and AA as predictor while 
adjusting for all covariates (Model 1). Secondly, a linear 
mixed model was used to assess the association of lung 
function with age acceleration by combining the 
available data at both time points for each individual, 
adjusting for all covariates from both time points 
(Model 2). This model incorporates sample and time 
point differences by introducing random intercepts for 
individuals and time points. In the third model, the 
association of lung function change (mL/year) with 
change in DNAmAge from baseline and follow-up 
(calculated from the difference between DNAmAge 
between two time points) was assessed (Model 3). The 
rate of lung function change was defined by 
    follow up base
follow up base
Lung function Lung function
Age Age
−
−
−
−
. For Model 3 
average BMI, average height, educational status at any 
time point, transition in asthma status, change in 
smoking status and centres were used as covariates. 
Samples with discrepancies in educational status and 
centres were removed. As epigenetic age acceleration 
has previously been found to be strongly associated 
with sex [36] (Supplementary Figure 1), and thus all 
models were a priori stratified by sex. In addition, the 
association between lung function and DNAmAgegrim, 
AAgrim, DNAmPAI1, and DNAmPAI1adj were assessed 
individually following Models 1 and 2. In this case, the 
associations were not stratified by sex. All models were 
performed in each cohort separately and effect estimates 
were meta-analysed using a fixed-effect model 
weighted by the inverse of the variance, using the R 
package “metafor” [37]. 
 
Associations of AA, except AAgrim, with lung function 
were further explored using an age stratified analysis 
(by 10 years: 30 – 40 years, 40 – 50 years, 50 – 60 
years, 60 – 70 years, and 70 – 80 years) using a linear 
mixed effects model.  
 
Further analyses were undertaken on female subjects at 
follow-up using menopausal status (pre-, peri-, and 
post-menopausal) to identify the effect of menopause on 
lung function and age accelerations using linear models 
adjusted for above mentioned covariates. The 
classifications of menopausal status for individual 
cohort have been described elsewhere [24, 38]. All 
statistical analyses were performed with R v3.3.2 [39]. 
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Supplementary Figures 
 
 
 
 
 
Supplementary Figure 1. Sex-specific effect on epigenetic age acceleration. 
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Supplementary Figure 2. Age stratified analyses comparing association between lung function and epigenetic age 
accelerations. X-axis represents stratifications by 10 years intervals. Y-axis represents the estimates (changed in lung function per year of 
epigenetic age acceleration in mLs/year) from the linear models with 95% confidence intervals. 
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Supplementary Figure 3. Cross-sectional meta-analysis results of association between DNAm GrimAge (DNAmGrim), Age-
adjusted measure of DNAm GrimAge (AAgrim), DNAm plasminogen activation inhibitor 1 (DNAmPAI1) and Age adjusted 
DNAm PAI-1 (DNAmPAI1adj) with lung function (FEV1, FVC, and FEV1/FVC) in SAPALDIA and ECRHS cohorts. The estimates have 
been measured with 95% confidence interval. 
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Supplementary Figure 4. Linear mixed model meta-analysis association of lung function (FEV1, FVC, and FEV1/FVC) with 
DNAm GrimAge (DNAmGrim), Age-adjusted measure of DNAm GrimAge (AAgrim), DNAm plasminogen activation inhibitor 1 
(DNAmPAI1) and Age adjusted DNAm PAI-1 (DNAmPAI1adj) two time points (baseline and follow-up). The estimates have been 
measured with 95% confidence interval. 
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Supplementary Tables 
 
Please browse Full Text version to see the data of Supplementary Tables 1 
 
Supplementary Table 1. Cross-sectional meta-analysis results of association between age acceleration and lung 
function of males and females in SAPALDIA and ECRHS. SAP = SAPALIDA, ECR = ECRHS. Lower and upper is the lower and 
upper ranges of 95% confidence interval of estimates. 
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Supplementary Table 2. Longitudinal meta-analysis results of association between age acceleration and lung 
function of males and females in SAPALDIA and ECRHS. SAP = SAPALIDA, ECR = ECRHS.  
A. Male 
Age acceleration Lung function Cohort Estimate Lower Upper P-value Meta p-value 
AAres FEV1 SAP 0.75 -6.33 7.84 0.83 0.61 
    ECR 1.53 -4.68 7.67 0.62   
  FVC SAP -2.35 -11.7 7.05 0.62 0.82 
    ECR 0.49 -7.54 8.44 0.90   
  FEV1/FVC SAP 0.0002 -0.0009 0.001 0.72 0.54 
    ECR 0.0002 -0.0007 0.001 0.62   
IEAA FEV1 SAP 2.86 -4.37 10.1 0.44 0.15 
   ECR 3.46 -2.34 9.16 0.23   
  FVC SAP -1.01 -10.6 8.64 0.84 0.96 
   ECR 0.85 -6.73 8.32 0.82   
  FEV1/FVC SAP 0.0004 -0.0008 0.002 0.55 0.25 
   ECR 0.0004 -0.0004 0.001 0.33   
EEAA FEV1 SAP -0.70 -9.60 8.19 0.88 0.13 
   ECR −10.10 −19.74 -0.46 0.04   
  FVC SAP −3.55 −15.43 8.33 0.56 0.4 
   ECR −3.84 -16.36 8.68 0.55   
  FEV1/FVC SAP -0.0002 -0.001 0.0009 0.43 0.43 
   ECR -0.0003 -0.001 0.0006 0.05  
 
B. Female 
Age acceleration Lung function Cohort Estimate Lower Upper P-value Meta- p-value 
AAres FEV1 SAP -4.12 -8.35 0.108 0.056 0.23 
    ECR -0.09 -3.34 3.13 0.96   
  FVC SAP -3.94 -9.78 1.88 0.18 0.06 
    ECR -2.84 -7.06 1.36 0.19   
  FEV1/FVC SAP -0.0005 -0.001 0.0004 0.29 1.0 
    ECR 0.0002 -0.0004 0.0008 0.48   
IEAA FEV1 SAP -3.66 -8.1 0.77 0.11 0.34 
   ECR 0.22 -3.57 3.98 0.91   
  FVC SAP -2.8 -8.93 3.31 0.37 0.13 
   ECR -2.99 -7.89 1.88 0.23   
  FEV1/FVC SAP -0.0005 -0.001 0.0005 0.36 0.98 
   ECR 0.0003 -0.0004 0.0009 0.48   
EEAA FEV1 SAP −3.21 −8.66 2.24 0.25 0.05 
   ECR −3.88 −8.74 0.98 0.12   
  FVC SAP −2.43 −9.90 5.04 0.52 0.13 
   ECR −4.60 −10.91 1.71 0.15   
  FEV1/FVC SAP -0.0002 -0.001 0.0006 0.29 0.28 
   ECR -0.0005 -0.001 0.0002 0.58   
Lower and upper is the lower and upper ranges of 95% confidence interval of estimates. 
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Supplementary Table 3. Longitudinal meta-analysis results of association between age acceleration and rate of lung 
function changes over baseline and follow-up of males and females in SAPALDIA and ECRHS. 
A. Male 
Age acceleration Lung function Cohort Estimate Lower Upper P-value Meta p-value 
AAres FEV1 SAP 0.28 -0.80 1.36 0.61 0.22 
   ECR 0.39 -0.29 1.06 0.26   
  FVC SAP 0.54 -1.19 2.27 0.54 0.17 
   ECR 0.57 -0.36 1.5 0.23   
  FEV1/FVC SAP -6.2x10-05 -0.0002 0.0001 0.50 0.92 
   ECR 1.4x10
-05 -9.1x10-05 0.0001 0.79   
IEAA FEV1 SAP 0.55 -0.52 1.63 0.31 0.75 
   ECR 0.51 -0.12 1.13 0.11   
  FVC SAP 0.44 -1.29 2.17 0.62 0.11 
   ECR 0.67 -0.19 1.54 0.13   
  FEV1/FVC SAP -1.2x10-05 -0.0002 0.0002 0.90 0.06 
   ECR 2.1x10
-05 -7.7 x10-05 0.0001 0.67   
EEAA FEV1 SAP 0.20 -1.13 1.54 0.76 0.51 
   ECR 0.51 -0.12 1.13 0.11   
  FVC SAP 0.21 -1.94 2.35 0.85 0.57 
   ECR 0.67 -0.19 1.54 0.13   
  FEV1/FVC SAP 5.8 x10-05 -0.0002 0.0003 0.60 0.98 
   ECR 2.1 x10
-05 -7.7 x10-05 0.0001 0.67   
 
B. Female 
Age acceleration Lung function Cohort Estimate Lower Upper P-value Meta p-value 
AAres FEV1 SAP -0.23 -0.84 0.39 0.47 0.38 
   ECR 0.22 -0.10 0.54 0.17   
  FVC SAP 0.22 -0.69 1.13 0.64 0.98 
   ECR -0.05 -0.47 0.36 0.81   
  FEV1/FVC SAP -0.0001 -0.0003 2.97 x10-05 0.12 0.17 
   ECR 6.2 x10-05 4.3 x10-05 0.0001 0.04   
IEAA FEV1 SAP -0.18 -0.82 0.46 0.58 0.29 
   ECR 0.30 -0.08 0.67 0.12   
  FVC SAP 0.34 -0.60 1.29 0.48 0.81 
   ECR -0.02 -0.51 0.47 0.92   
  FEV1/FVC SAP -0.0001 -0.0003 4.5 x10-05 0.17 0.16 
   ECR 7.5 x10-05 6.7 x10-05 0.0001 0.03   
EEAA FEV1 SAP -0.12 -0.91 0.68 0.77 0.59 
   ECR 0.30 -0.08 0.67 0.12   
  FVC SAP 0.52 -0.66 1.69 0.39 0.62 
   ECR -0.02 -0.51 0.47 0.92   
  FEV1/FVC SAP -0.0002 -0.0004 -3.3 x10-06 0.05 0.98 
   ECR 7.5 x10-05 6.7 x10-06 0.0001 0.032   
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Supplementary Table 4. Comparison between two meta-analyses models (with and without menopausal status). 
The difference (z-score) between the estimates from two models is calculated by Wald type test by the following 
equation: 
 
1 2
2 2
1 2[ ] [ ]
z
SE SE
 −
=
 + 
 
 
Here, 1  2  are estimates and 1[ ]SE  , 2[ ]SE   are corresponding standard errors of two meta-analyses. 
 
    z -score P-value 
AAres FEV1 -0.042 0.966 
  FVC -0.009 0.993 
  FEV1/FVC 0.779 0.28 
      
IEAA FEV1 -0.087 0.931 
  FVC -0.044 0.965 
  FEV1/FVC 0.416 0.677 
EEAA FEV1 -0.105 0.917 
  FVC -0.09 0.928 
  FEV1/FVC 0.095 0.924 
 
Supplementary Table 5. Association between menopausal status and lung function.  
 Lung function Estimate Lower Upper P-value 
Pre- vs. Peri- 
menopause 
FEV1 -6 -130 117 0.919 
 FVC 11 -140 163 0.882 
 FEV1/FVC -0.002 -0.019 0.016 0.845 
Pre- vs. Post- 
menopause 
FEV1 -109 -222 3 0.057 
 FVC -83 -212 46 0.209 
 FEV1/FVC -0.009 -0.027 0.01 0.353 
Peri- vs. Post- 
menopause 
FEV1 -62 -153 29 0.18 
 FVC -27 -130 76 0.607 
 FEV1/FVC -0.011 -0.026 0.005 0.175 
The units for estimates of FEV1 and FVC are in mL. Lower and upper is the lower and upper ranges of 95% confidence interval 
of estimates. 
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Supplementary Table 6. Association between menopausal status and age acceleration. 
  Beta Lower Upper P-value 
Pre- vs. Peri- 
menopause 
AAres -0.135 -1.27 0.997 0.814 
 IEAA -0.397 -1.5 0.704 0.478 
 EEAA 0.248 -0.617 1.11 0.573 
Pre- vs. Post- 
menopause 
AAres -0.129 -0.971 0.714 0.764 
 IEAA -0.221 -1.02 0.575 0.585 
 EEAA -0.0345 -0.69 0.62 0.918 
Peri- vs. Post- 
menopause 
AAres 0.007 -0.948 0.961 0.989 
 IEAA 0.176 -0.738 1.09 0.705 
 EEAA -0.282 -1.04 0.479 0.467 
The units for estimate of age accelerations are in years. Lower and upper is the lower and upper ranges of 95% confidence 
interval of estimates. 
 
Please browse Full Text version to see the data of Supplementary Table 7 
 
Supplementary Table 7. Age stratified cross-sectional analysis results of association between age acceleration and 
lung function of females in SAPALDIA and ECRHS. Lower and upper is the lower and upper ranges of 95% confidence interval of 
estimates.  
 
